Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 11, Issue 7, Pages 1115-1130Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.11.61
Keywords
antimitotic agents; BI 2536, BI 6727 (volasertib); GSK461364; GW843682X; HMN-214; NMS-P937 (NMS1286937); novel anticancer drugs; ON 01910.Na; Polo-like kinase (Plk) inhibitors; TAK-960; TKM-080301
Categories
Funding
- Boehringer Ingelheim
- Novartis
- Roche
Ask authors/readers for more resources
Polo-like kinase 1 (Plk1) inhibitors belong to a new class of drugs for the treatment of malignant diseases. They selectively act against a target (Plk1) which is involved in different stages of mitosis such as centrosome maturation, spindle formation, chromosome separation and cytokinesis. Because Plk1 is mainly expressed in proliferating tissues and overexpressed in cancers, its inhibition is potentially less prone to toxicities associated with current antimitotic agents, which also act on nondividing cells. Several Plk1 inhibitors are being evaluated as cancer treatment drugs. Based on the essential role of Plk1 during mitosis, Plk1 inhibitors target all rapidly dividing cells irrespective of their tumor suppressor or oncogene mutations. In this article, their mechanisms of action, efficacy and toxicity profile are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available